JP2019518764A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518764A5 JP2019518764A5 JP2018566834A JP2018566834A JP2019518764A5 JP 2019518764 A5 JP2019518764 A5 JP 2019518764A5 JP 2018566834 A JP2018566834 A JP 2018566834A JP 2018566834 A JP2018566834 A JP 2018566834A JP 2019518764 A5 JP2019518764 A5 JP 2019518764A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- acyclic
- alkyl
- cyclopropyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 25
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 10
- AHHWIHXENZJRFG-UHFFFAOYSA-N oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 claims 10
- 125000006682 monohaloalkyl group Chemical group 0.000 claims 8
- 125000006684 polyhaloalkyl group Polymers 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 7
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 108010021592 Pantothenate kinase Proteins 0.000 claims 5
- 102100024122 Pantothenate kinase 1 Human genes 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 claims 2
- 239000005516 coenzyme A Substances 0.000 claims 2
- 229940093530 coenzyme a Drugs 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000008482 dysregulation Effects 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 0 CC(C)N1C=*CC*1 Chemical compound CC(C)N1C=*CC*1 0.000 description 6
- PGTQKVQDZHXLOP-UHFFFAOYSA-N CC(C)c1cnc(C)cn1 Chemical compound CC(C)c1cnc(C)cn1 PGTQKVQDZHXLOP-UHFFFAOYSA-N 0.000 description 1
- VEUZQDDGNJYJRU-UHFFFAOYSA-N CCC(C1)N(C(C)C)C(C)CN1C(C)C Chemical compound CCC(C1)N(C(C)C)C(C)CN1C(C)C VEUZQDDGNJYJRU-UHFFFAOYSA-N 0.000 description 1
- OJUIRGBRDTZUKO-UHFFFAOYSA-N CCC(CNC(C)C)NC(C)C Chemical compound CCC(CNC(C)C)NC(C)C OJUIRGBRDTZUKO-UHFFFAOYSA-N 0.000 description 1
- SFMFETJWUJVYSS-UHFFFAOYSA-N CCCNCCNC(C)C Chemical compound CCCNCCNC(C)C SFMFETJWUJVYSS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662354012P | 2016-06-23 | 2016-06-23 | |
| US62/354,012 | 2016-06-23 | ||
| PCT/US2017/039037 WO2017223474A1 (en) | 2016-06-23 | 2017-06-23 | Small molecule modulators of pantothenate kinases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019518764A JP2019518764A (ja) | 2019-07-04 |
| JP2019518764A5 true JP2019518764A5 (enExample) | 2020-08-06 |
| JP7078555B2 JP7078555B2 (ja) | 2022-05-31 |
Family
ID=60783428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018566834A Active JP7078555B2 (ja) | 2016-06-23 | 2017-06-23 | パントテン酸キナーゼの小分子調節剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10899734B2 (enExample) |
| EP (1) | EP3474667A4 (enExample) |
| JP (1) | JP7078555B2 (enExample) |
| KR (1) | KR102459256B1 (enExample) |
| CN (1) | CN109561680B (enExample) |
| AU (1) | AU2017281907B2 (enExample) |
| CA (1) | CA3025260A1 (enExample) |
| DO (1) | DOP2018000293A (enExample) |
| IL (1) | IL263649B (enExample) |
| MX (1) | MX383697B (enExample) |
| SA (1) | SA518400696B1 (enExample) |
| SG (1) | SG11201811023UA (enExample) |
| WO (1) | WO2017223474A1 (enExample) |
| ZA (1) | ZA201808099B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383697B (es) | 2016-06-23 | 2025-03-14 | St Jude Childrens Res Hospital Inc | Moduladores de moleculas peque?as de pantotenato cinasas |
| KR102728619B1 (ko) * | 2017-12-27 | 2024-11-08 | 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 | 판토테네이트 키나제의 소분자 조절제 |
| CA3086711A1 (en) * | 2017-12-27 | 2019-07-04 | St. Jude Children's Research Hospital, Inc. | Use of arylpiperazine-1-carboxamide derivatives in the treatment of coenzyme a-mediated disorders |
| JPWO2020017569A1 (ja) * | 2018-07-17 | 2021-12-02 | 日本ケミファ株式会社 | Ｔ型カルシウムチャネル阻害剤 |
| EP3946312A4 (en) * | 2019-03-27 | 2023-04-19 | St. Jude Children's Research Hospital | SMALL MOLECULE MODULATORS OF PANK |
| WO2020203609A1 (ja) * | 2019-03-29 | 2020-10-08 | 日本ケミファ株式会社 | 掻痒を治療するためのｔ型カルシウムチャネル阻害剤の使用 |
| JP2022081710A (ja) * | 2019-03-29 | 2022-06-01 | ユーティアイ リミテッド パートナーシップ | 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用 |
| US11752149B2 (en) | 2019-12-02 | 2023-09-12 | Pipeline Therapeutics, Inc. | Muscarinic acetylcholine M1 receptor antagonists |
| EP4262814A4 (en) * | 2020-12-16 | 2025-02-26 | St. Jude Children's Research Hospital, Inc. | Methods of treating disorders associated with castor |
| TW202417421A (zh) * | 2022-08-08 | 2024-05-01 | 美商雅捷可斯治療公司 | 作為ｊａｋ２抑制劑之雜環醯胺及脲化合物 |
| CN119745886A (zh) * | 2025-01-20 | 2025-04-04 | 中国药科大学 | 4-异丙苯基乙酰哌嗪在制备抗阿尔茨海默病药物中的应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6894063B2 (en) * | 2000-09-14 | 2005-05-17 | Schering Corporation | Substituted urea neuropeptide Y Y5 Receptor antagonists |
| EP1322628A2 (en) * | 2000-09-14 | 2003-07-02 | Schering Corporation | Substituted urea neuropeptide y y5 receptor antagonists |
| AU2003236500B9 (en) * | 2002-06-12 | 2009-07-02 | Chemocentryx, Inc. | 1-aryl-4-substituted piperazine derivatives for use as CCR1 antagonists for the treatment of inflammation and immune disorders |
| US20050256130A1 (en) | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
| US7262194B2 (en) | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
| AR044688A1 (es) | 2003-06-12 | 2005-09-21 | Euro Celtique Sa | Agentes terapeuticos utiles para el tratamiento del dolor |
| US7759348B2 (en) | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
| JP4831577B2 (ja) * | 2003-07-30 | 2011-12-07 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ピリダジン誘導体および治療剤としての用途 |
| US20060035884A1 (en) | 2004-05-20 | 2006-02-16 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
| US7754724B2 (en) | 2005-06-30 | 2010-07-13 | Dow Agrosciences Llc | N-substituted piperazines |
| CA2668811A1 (en) | 2006-11-07 | 2008-06-05 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
| CA2690378A1 (en) | 2007-06-25 | 2008-12-31 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
| DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
| US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| CN103619825B (zh) | 2011-07-01 | 2015-10-14 | 瑞敏德股份有限公司 | 可用于治疗神经退化性疾病的1,2,4-噻二唑-5-基哌嗪衍生物 |
| CA2873097A1 (en) | 2012-05-11 | 2013-11-14 | Todd M. Hansen | Pyridazine and pyridine derivatives as nampt inhibitors |
| TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
| CN107922377A (zh) | 2015-04-17 | 2018-04-17 | 美国印第安纳大学研究和技术公司 | 乙肝病毒组装效应子 |
| MX383697B (es) | 2016-06-23 | 2025-03-14 | St Jude Childrens Res Hospital Inc | Moduladores de moleculas peque?as de pantotenato cinasas |
-
2017
- 2017-06-23 MX MX2018015170A patent/MX383697B/es unknown
- 2017-06-23 EP EP17816310.1A patent/EP3474667A4/en active Pending
- 2017-06-23 CA CA3025260A patent/CA3025260A1/en active Pending
- 2017-06-23 US US16/307,473 patent/US10899734B2/en active Active
- 2017-06-23 WO PCT/US2017/039037 patent/WO2017223474A1/en not_active Ceased
- 2017-06-23 CN CN201780043423.3A patent/CN109561680B/zh active Active
- 2017-06-23 KR KR1020197000671A patent/KR102459256B1/ko active Active
- 2017-06-23 SG SG11201811023UA patent/SG11201811023UA/en unknown
- 2017-06-23 JP JP2018566834A patent/JP7078555B2/ja active Active
- 2017-06-23 AU AU2017281907A patent/AU2017281907B2/en active Active
-
2018
- 2018-11-29 ZA ZA2018/08099A patent/ZA201808099B/en unknown
- 2018-12-11 IL IL263649A patent/IL263649B/en unknown
- 2018-12-19 SA SA518400696A patent/SA518400696B1/ar unknown
- 2018-12-21 DO DO2018000293A patent/DOP2018000293A/es unknown
-
2020
- 2020-12-14 US US17/120,800 patent/US20210246113A1/en active Pending